undefined undefined
NaN.000
NaN.00%
Merus (NASDAQ:MRUS) has received breakthrough therapy designation for its drug candidate petosemtamab in the treatment of certain patients with head and neck cancer. Petosemtamab received the designat...
05-14 00:47
Merus N.V. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for petosemtamab for the treatment of patients with recurrent or metastatic head and neck squamous
05-13 20:23
Needham:重申Merus(MRUS.US)评级,由买入调整至买入评级, 目标价66.00美元。
05-13 18:50
来源:华兴资本 “华兴资本医疗与生命科技行业周报”定期发布,专注从资本角度解读一周数据,并提供最新行业观察。 医疗与生命科技是华兴资本多年来关注并深耕的领域,目...
05-13 09:30
Vitesse Energy, Inc. (VTS) declares $0.525/share quarterly dividend, 5.0% increase from prior dividend of $0.50. Forward yield 9.30% Payable June 28; for shareholders of record June 14; ex-div June 14...
05-07 04:48
Merus (NASDAQ:MRUS) said the FDA has accepted its biologics license application for priority review of its drug candidate Zeno, also known as zenocutuzumab, for the treatment of non-small cell lung ca...
05-07 04:45
信达生物制药宣布,任命张苏华(Samuel Zhang)博士为全球首席商务官(CBO)。张博士在加入信达生物之前曾担任亘喜生物和NeoImmune Tech公司...
04-30 15:31
4月30日信达生物制药宣布任命张苏华(Samuel Zhang)为全球首席商务官(CBO)。张苏华将负责信达生物在全球业务的战略规划和商务拓展工作向公司创始人...
04-30 12:55
Visa to streamline access to select services via the AWS partner network for its cloud-native fintech, financial institution, and enterprise clientsVisa (NYSE:V), a world leader in global digital payments, announced
04-25 20:09
欢迎关注凯莱英药闻 2024年4月21日,贝达药业发布2023 年年报和2024年Q1季报;2023 年公司实现营业收入24.56 亿元,同比增长3.35%...
04-22 14:14